FORT COLLINS, Colo.--(BUSINESS WIRE)--Inviragen has been invited to participate in a press conference hosted by BIO Ventures for Global Health (BVGH) during the annual Biotechnology Industry Organization international convention taking place June 18-21, 2012 at the Boston Convention & Exhibition Center, MA. During the press briefing, which is being held at 9:00am ET on June 18, a report developed by BVGH and BIO titled Biotechnology: Bringing Innovation to Neglected Disease Research and Development will be publicly released. The report discusses the role of biotechnology companies in developing innovative new health care products for neglected diseases in the developing world. Inviragen’s efforts to develop vaccines for unmet needs in Asia and the Americas are highlighted in the report. Dr. Dan Stinchcomb, chief executive officer of Inviragen will join a triad of industry executives who will provide insight on their research and development of diagnostics, drugs and vaccines to address neglected diseases worldwide.
"Inviragen is developing a dengue vaccine, DENVax, which is in Phase 2 clinical testing, and a hand, foot and mouth disease vaccine that recently completed a Phase 1 study. These are two of the many tropical diseases that impact billions of people in the developing world." Dr. Stinchcomb continued, “BVGH’s efforts to improve access to funding and market information should encourage more biotechnology companies to join in the development of therapeutics, vaccines and diagnostics for these and other neglected diseases. We at Inviragen share BVGH’s commitment to this effort and look forward to supporting them on the 18th when they unveil their newest industry report.”
About Inviragen, Inc.
Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen’s vaccine to protect against dengue fever is in Phase 2 clinical testing. A vaccine designed to protect children from hand, foot and mouth disease has completed Phase 1 clinical testing. Vaccines to protect against chikungunya and Japanese encephalitis, which affect millions of individuals in Asia, are in development. Vaccines in preclinical research stages include a second generation human papilloma virus vaccine, vaccines to protect against new forms of influenza and a combination plague/smallpox vaccine for biodefense. Founded in 2005 with offices in Colorado, Wisconsin and Singapore, Inviragen’s investors include Charter Life Sciences (Palo Alto, CA), Venture Investors (Madison, WI), Bio*One Capital Pte. Ltd. (Singapore) and Phillip Private Equity (Singapore). See www.inviragen.com for more details.
About BIO Ventures for Global Health
BIO Ventures for Global Health (BVGH) is a non-profit organization whose mission is to save lives by accelerating the development of novel drugs, vaccines, and diagnostics coming from the biotechnology industry that address the unmet medical needs of the developing world. The organization works at the crossroads of biotechnology and global health to find the common ground between the goals of the global health community and the pragmatic needs of companies. For more information, please visit www.bvgh.org.